LobbyingOye Therepeutics lobbying by quarter
Oye Therepeutics's latest lobbying report covers Q2 2026, at $10K. The four quarters Q4 2025–Q3 2026 total $30K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Oye Therepeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $30K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $30K | 1 |
| Q2 2023 | $30K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $30K | 1 |
| Q1 2024 | $30K | 1 |
| Q2 2024 | $30K | 1 |
| Q3 2024 | $30K | 1 |
| Q4 2024 | $30K | 1 |
| Q1 2025 | $30K | 1 |
| Q2 2025 | $30K | 1 |
| Q3 2025 | $10K | 1 |
| Q4 2025 | $10K | 1 |
| Q1 2026 | $10K | 1 |
| Q2 2026 | $10K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$370K · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Defense, Dept of (DOD)15 reports
- Executive Office of the President (EOP)15 reports
- Food & Drug Administration (FDA)15 reports
- HOUSE OF REPRESENTATIVES15 reports
- Office of Management & Budget (OMB)15 reports
- Office of Natl Drug Control Policy (NDCP)15 reports
- Office of Science & Technology Policy (OSTP)15 reports
- SENATE15 reports
- Health & Human Services, Dept of (HHS)7 reports
Firms it paid
| Firm | ||
|---|---|---|
| Bell & Lindsay | $370K | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARK F LINDSAY | US House Staff | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Bell & Lindsay | $10K |
| 04/20for Q1 | Bell & Lindsay | $10K |
| 02/11for Q4 2025 | Bell & Lindsay | $10K |
| 25/10/20for Q3 2025 | Bell & Lindsay | $10K |
| 25/07/21for Q2 2025 | Bell & Lindsay | $30K |
| 25/04/21for Q1 2025 | Bell & Lindsay | $30K |
| 25/01/21for Q4 2024 | Bell & Lindsay | $30K |
| 24/10/21for Q3 2024 | Bell & Lindsay | $30K |
| 24/07/19for Q2 2024 | Bell & Lindsay | $30K |
| 24/04/19for Q1 2024 | Bell & Lindsay | $30K |
| 24/01/19for Q4 2023 | Bell & Lindsay | $30K |
| 23/10/20for Q3 2023 | Bell & Lindsay | $30K |
| 23/07/20for Q2 2023 | Bell & Lindsay | $30K |
| 23/04/20for Q1 2023 | Bell & Lindsay | $30K |
| 23/01/19for Q4 2022 | Bell & Lindsay | $30K |